Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PENTOTHAL vs ABILIFY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potentiates GABA-A receptor activity, enhancing inhibitory neurotransmission; also reduces excitatory glutamate signaling.
Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.
Induction of general anesthesia,Induction of coma for increased intracranial pressure,Status epilepticus (off-label)
Schizophrenia,Bipolar I disorder (acute manic/mixed episodes, maintenance),Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
Induction: 3-5 mg/kg IV; Maintenance: 25-75 mg IV as needed; Rectal: 25 mg/kg (max 1.5 g) for induction.
Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).
Terminal elimination half-life is 5-12 hours (mean 8 hours) in adults. Prolonged with hepatic impairment, obesity, or high doses due to saturation of redistribution and metabolism.
Aripiprazole: 75 hours; dehydro-aripiprazole: 94 hours. Steady-state reached in ~14 days.
Hepatic; primarily via CYP2C9 and other CYP450 enzymes.
Hepatic metabolism primarily via CYP3A4 and CYP2D6; also by dehydrogenation and N-dealkylation.
Hepatic metabolism (approx. 80%), renal excretion of metabolites (20-30%) and unchanged drug (0.3-1%). Biliary/fecal elimination is negligible.
Renal (25% unchanged, 18% as dehydro-aripiprazole) and fecal (55% unchanged and metabolites).
Approximately 72-86% bound, primarily to albumin (with some binding to lipoproteins).
>99% bound to albumin and alpha-1-acid glycoprotein.
Vd = 1.0-2.5 L/kg (mean 1.5 L/kg). High Vd due to extensive tissue distribution, including brain and fat; correlates with high lipid solubility.
4.9 L/kg (high distribution into tissues).
IV: 100%. Rectal: approximately 60-80% (with variability). IM: approximately 60-70%. Oral: negligible due to extensive first-pass metabolism (not used clinically).
Oral: 87% (tablet and solution); IM: 100%.
No specific GFR-based adjustment; use with caution in severe renal impairment due to prolonged effects.
No dosage adjustment required for renal impairment; not removed by hemodialysis.
Reduce dose by 50% in Child-Pugh B and C; monitor for prolonged sedation.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
Induction: 5-6 mg/kg IV; Maintenance: 1-2 mg/kg IV as needed; Rectal: 25 mg/kg (max 1.5 g).
Schizophrenia (13-17 years): 2 mg/day, target 10-25 mg/day. Bipolar mania (10-17 years): 2 mg/day, target 10-30 mg/day. Autism irritability (6-17 years): 2 mg/day, target 5-15 mg/day.
Reduce induction dose to 2-3 mg/kg IV; use lower maintenance doses; increased risk of hypotension and respiratory depression.
Initiate at lower doses (e.g., 2-5 mg/day) and titrate slowly due to increased risk of adverse effects, especially orthostatic hypotension and cognitive decline.
WARNING: RESPIRATORY DEPRESSION AND APNEA; RESUSCITATIVE EQUIPMENT AND PERSONNEL MUST BE IMMEDIATELY AVAILABLE. INTRA-ARTERIAL INJECTION MAY CAUSE ARTERIAL SPASM, THROMBOSIS, AND GANGRENE.
Increased risk of death in elderly patients with dementia-related psychosis due to cerebrovascular events.
Respiratory depression, hypotension, laryngospasm, bronchospasm, cardiac arrhythmias, extravasation risk, and acute porphyria exacerbation.
Increased mortality in elderly dementia patients, suicidal thoughts/behaviors, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), orthostatic hypotension, leukopenia/neutropenia, seizures, body temperature dysregulation, dysphagia, impulse control disorders.
Hypersensitivity to barbiturates, acute porphyria, severe respiratory or cardiovascular instability, and inadequate airway management capability.
Known hypersensitivity to aripiprazole or any of its excipients.
No specific food interactions. However, avoid alcohol for at least 24 hours due to additive CNS depression.
Grapefruit juice may increase aripiprazole exposure; avoid concurrent intake. No other significant food interactions. Alcohol can enhance CNS depression; limit or avoid.
PENTOTHAL (thiopental) crosses the placenta. First trimester: limited human data, animal studies show no consistent teratogenicity. Second trimester: no specific malformation risk. Third trimester: prolonged maternal administration may cause neonatal respiratory depression, hypotonia, and withdrawal. Use only if clearly needed.
Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and third trimesters: neonates exposed in late pregnancy are at risk for extrapyramidal symptoms (EPS) and withdrawal syndrome including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder.
Thiopental is excreted in breast milk. M/P ratio is approximately 0.4–0.8. Infant dose is low (<1% of maternal weight-adjusted dose), but caution is advised due to potential CNS depression. American Academy of Pediatrics considers compatible with breastfeeding, but monitor infant for sedation.
Aripiprazole is excreted in human breast milk; milk-to-plasma (M/P) ratio is approximately 0.5 to 1.0. Relative infant dose is estimated to be 1-3% of maternal weight-adjusted dose. Limited data; use with caution. Monitor infant for sedation, poor feeding, and abnormal movements.
Pregnancy may increase volume of distribution and clearance, but dosing adjustments for thiopental are not routinely recommended. Use lowest effective dose due to increased sensitivity to barbiturates. For cesarean section, standard induction doses (3-5 mg/kg IV) are used; reduced doses may be needed if combined with other sedatives.
No established pharmacokinetic data; however, pregnancy-induced physiological changes (increased plasma volume, renal clearance) may lower aripiprazole levels. Monitor therapeutic efficacy and consider dose adjustment if symptom exacerbation. No specific dose modification guidelines available; titrate based on clinical response and tolerability.
Pentothal (thiopental) is an ultra-short-acting barbiturate used for induction of anesthesia. It causes dose-dependent respiratory depression and hypotension. Administer only in a controlled setting with resuscitation equipment. Note that it is highly alkaline (p H 10-11) and extravasation causes severe tissue necrosis. Also, it is contraindicated in porphyria.
Abilify (aripiprazole) is a partial dopamine agonist, which reduces the risk of extrapyramidal symptoms and hyperprolactinemia compared to full antagonists. Monitor for akathisia, especially during dose titration. QT prolongation risk is lower than with other antipsychotics; use caution in patients with cardiac disease. Avoid use in dementia-related psychosis due to increased mortality. Therapeutic effects may take 2-4 weeks; full response often requires 6-8 weeks.
You will receive this medication only under the supervision of an anesthesiologist.,It will cause you to fall asleep quickly and you may feel drowsy for several hours after the procedure.,Do not drive or operate machinery for at least 24 hours after receiving this medication.,Inform your doctor if you have a history of porphyria, liver disease, or allergies to barbiturates.,You may experience a bad taste or cough upon injection.
Take exactly as prescribed; do not stop abruptly without consulting your doctor.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and grapefruit juice as they can alter drug levels.,Report any uncontrolled muscle movements, especially in face or tongue.,Monitor weight and blood glucose regularly as it can cause metabolic changes.,If you miss a dose, take it as soon as you remember unless it's almost time for the next dose; do not double up.,Use effective contraception if of childbearing potential; discuss pregnancy plans with your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PENTOTHAL vs ABILIFY, answered by our medical review team.
PENTOTHAL is a Barbiturate Anesthetic that works by Potentiates GABA-A receptor activity, enhancing inhibitory neurotransmission; also reduces excitatory glutamate signaling.. ABILIFY is a Atypical antipsychotic that works by Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PENTOTHAL and ABILIFY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PENTOTHAL is: Induction: 3-5 mg/kg IV; Maintenance: 25-75 mg IV as needed; Rectal: 25 mg/kg (max 1.5 g) for induction.. The standard adult dose of ABILIFY is: Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PENTOTHAL and ABILIFY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PENTOTHAL is classified as Category C. PENTOTHAL (thiopental) crosses the placenta. First trimester: limited human data, animal studies show no consistent teratogenicity. Second trimester: no specific malformation risk.. ABILIFY is classified as Category C. Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and thir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.